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United Kingdom, and to describe differential persistence by treatment regimen.
Methods: We performed a retrospective cohort study at eight UK centres of ART-na€ıve adults
commencing ART between 2012 and 2015. Aggregate data were extracted from local treatment
databases. Time to discontinuation was compared for different third agents and NRTI back-
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402 J.M. Lewis et al.Results: 1949 patients contributed data to the analysis. Rate of third agent change was 28 per
100 person-years of follow up [95% CI 26e31] and NRTI backbone change of 15 per 100 person-
years of follow up [95% CI 14e17]). Rilpivirine, as co-formulated rilpivirine/tenofovir/emtrici-
tabine had a significantly lower discontinuation rate than all other third agents and, excluding
single tablet regimens, co-formulated tenofovir/emtricitabine had a significantly lower discon-
tinuation rate than co-formulated abacavir/lamivudine. The reasons for discontinuation were
not well recorded.
Conclusions: Treatment discontinuation is not an uncommon event. Rilpivirine had a signifi-
cantly lower discontinuation rate than other third agents and tenofovir/emtricitabine a lower
rate than co-formulated abacavir/lamivudine.
ª 2017 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).Introduction
The extent to which a patient takes medication in accor-
dance with the expectations of the prescribing clinician can
be quantified by a variety of methods. Early antiretroviral
therapy (ART) for HIV necessitated extremely high levels of
adherence,1 which can be defined as the degree of confor-
mity to dose and dose interval.2 As a result of these require-
ments, studies exploring the consequences of poor
adherence1,3e5 as well as strategies for supporting compli-
ance6,7 to ART are well represented in the literature.
Persistence, however, refers to the length of time that a
patient remains on therapy and can be defined as the
duration of time from initiation to discontinuation.2 Persis-
tency data for ART are lacking but can provide information
on the comparative effectiveness, durability and tolera-
bility of modern ART regimens in real-world patient popula-
tions. Differential persistence across different patient
populations or according to patient characteristics can pro-
vide data to inform individualisation of treatment. There-
fore, we performed a study to describe persistence with
different ART regimens for treatment na€ıve patients start-
ing ART in the United Kingdom (UK). We extracted data
from established local treatment databases at eight UK
HIV treatment centres to perform a retrospective cohort
study comparing persistence across ART regimens in treat-
ment na€ıve patients commencing therapy. In particular,
we aimed to compare persistence across multiple tablet
regimens (MTRs) by third agents and nucleo(t)side reverse
transcriptase inhibitor (NRTI) backbone, and single tablet
regimens (STRs).
Methods
Eight UK specialist HIV treatment centres contributed data
to this cohort; four in London, two in Manchester, one each
in Liverpool and Brighton. Aggregate data were extracted
from local treatment databases and/or clinical records.
Inclusion criteria were: all treatment na€ıve people living
with HIV commencing antiretroviral therapy between
January 2012 and June 2015. Considered regimens were
those within the British HIV association (BHIVA) guidelines
at the time of the study and included in regional treatment
guidelines: co-formulated tenofovir/emtricitabine (TDF/
FTC) or abacavir/lamivudine (ABC/3TC) with ritonavirboosted darunavir (DRV/r), ritonavir-boosted atazanavir
(ATV/r), efavirenz (EFV) or raltegravir (RAL), and co-
formulated EFV/TDF/FTC or co-formulated rilpivirine
(RPV)/TDF/FTC. All data were extracted in aggregate
anonymised form and identifiable individual level data
were not used. Patients were followed from date of ART
start to the first date of treatment discontinuation, admin-
istrative censoring (June 2015) or last available viral load,
and treatment discontinuation was defined to include
stopping or switching therapy. Time to discontinuation
was compared between ART regimens using incidence
rates, with 95% confidence intervals calculated assuming
a Poisson distribution when fewer than 20 evens, and with a
Normal approximation otherwise. Statistical tests of differ-
ence in incidence rates, where carried out, used Poisson
regression. As this study used only anonymised, aggregate
data, ethical approval was not required.
Results
A total of 2851 patients were initially identified; at two
centres data were recorded by drug and not by regimen so
for 902 patients taking EFV, TDF and FTC it was not possible
to determine if they were taking STR or MTR. These
patients were excluded from the analysis, leaving 1949
individuals. The median age was 37 (IQR 30e45) 1682/1949
[86%] were men, 1368/1949 [70%] men who have sex with
men (MSM) and 1371/1949 [70%] of white ethnicity. Pre-
treatment CD4 count data were missing for 138 patients;
for the remainder, the median CD4 count was 343 (IQR
219e492) and 281/1811 [16%] patients had a CD4 count of
less than 200 cells/mm3. There was missing pre-treatment
viral load data for 75 patients; for the remainder 729/
1874 [39%] had a viral load of greater than 100,000
copies/ml. The breakdown of the included regimens is
shown in Table 1. Full baseline characteristics of the
included patients are shown in Table 2.
During 2215 patient-years of follow-up e a mean follow
up of 1.1 years per patient e 339 individuals changed the
NRTI backbone, including as part of STR change (15 per 100
person-years [95% CI 14e17]) (Fig. 1). Comparing only MTR
regimens, the rate of TDF/FTC discontinuation was signifi-
cantly lower than ABC/3TC (10 [95% CI 9e12] vs 17
[12e22] per 100 person-years p < 0.01). During 1972 years
of follow up e a mean follow up of 1.0 years per patient e
Table 1 Included ARV regimens.
‘Third’ drug NRTI backbone All CD4 count <200 cells/mm3 VL >100,000 copies/ml
Co-formulated EFV/TDF/FTC n (%) 406 (20.8%) 86 (21.6%) 153 (21.0%)
Co-formulated RPV/TDF/FTC n (%) 264 (13.6%) 19 (4.8%) 17 (2.3%)
DRV/r TDF/FTC n (%) 550 (28.2%) 149 (37.3%) 285 (39.1%)
DRV/r 3TC/ABC n (%) 61 (3.1%) 15 (3.8%) 12 (1.7%)
ATV/r TDF/FTC n (%) 212 (10.9%) 32 (8.0%) 109 (15.0%)
ATV/r 3TC/ABC n (%) 88 (4.5%) 17 (4.3%) 11 (1.5%)
EFV TDF/FTC n (%) 67 (3.4%) 23 (5.8%) 36 (4.9%)
EFV 3TC/ABC n (%) 105 (5.4%) 14 (3.5%) 9 (1.2%)
RAL TDF/FTC n (%) 196 (10.1%) 44 (11.0%) 97 (13.3%)
Total 1949 (100%) 399 (100%) 729 (100%)
EFV Z efavirenz, TDFZ tenofovir, FTC Z emtricitabine, DRV/r Z ritonavir boosted darunavir, ATV/r Z Ritonavir boosted atazanavir,
RAL Z raltegravir, 3TC Z lamivudine, ABC Z abacavir, NRTI Z nucleoside reverse transcriptase, VL Z viral load.
Persistence with ART in the UK 403third agent change was observed in 557 patients, including
as part of STR change (28 per 100 person-year [95% CI
26e31]) (Fig. 1). The MTR third agents DRV/r, ATV/r, EFV,
RAL had similar discontinuation rates (Fig. 1), as did EFV/
TDF/FTC. However, RPV/TDF/FTC had a significantly lower
rate (7 per 100 person-years [95% CI 4e11] p < 0.01 for
comparison to all 3rd agent discontinuations.)
The reasons for discontinuations are shown in Figs. 2 and
3. Of all MTR NRTI backbone discontinuations, the reason
for discontinuation was not recorded in 68/171 [40%] ofTable 2 Baseline characteristics of study participants.
All
Number 1949
Gender Male n (%) 1682 (8
Age (years) Median (IQR) 37 (30e
Risk for HIV acquisition MSM 1368 (7
Heterosexual 413 (21
Other 168 (8.6
Ethnicity White 1371 (7
Black African 259 (13
Black Caribbean 47 (2.4%
Other 271 (13
Viral load Median (IQR) log cps/ml 4.8 (4.3
<1000 cps/ml 99 (5.1%
1000e9999 cps/ml 230 (11
10,000e99,999 cps/ml 816 (41
100,000 cps/ml 729 (37
Unknown 75 (3.9%
CD4 count (cells/mm3) Median (IQR) 343 (21
<50 118 (6.1
50e199 281 (14
200e349 529 (27
350e499 450 (23
500 433 (22
Unknown 138 (7.1
Year of starting ART 2012 694 (35
2013 635 (32
2014 570 (29
2015 50 (2.6%
VL Z [HIV] viral load. ART Z antiretroviral therapy.cases, and, of note, in the majority (34/47 [72%]) cases of
ABC/3TC discontinuation. Of the remainder, 48/103 [47%]
discontinuations were due to simplification or patient
choice, 32/103 [31%] due to toxicity and 3/103 [3%] were
due to virologic failure. Of all third agent and STR discon-
tinuations, the reason for discontinuation was not recorded
in 177/557 [32%] of cases. Of the remainder, 230/380 [61%]
were due to toxicity, 85/380 [22%] were due to simplifica-
tion or patient choice, and 17/380 [4%] due to virologic
failure.CD4 <200 cells/mm3 VL >100,000 copies/ml
399 729
6.3%) 303 (75.9) 646 (88.6)
45) 42 (34e49) 38 (31e46)
0.2%) 191 (47.9%) 519 (71.2%)
.2%) 169 (42.4%) 155 (21.3%)
%) 39 (9.8%) 55 (7.5%)
0.4%) 209 (52.4%) 541 (74.2%)
.3%) 110 (27.6%) 89 (12.2%)
) 13 (3.3%) 13 (1.8%)
.9%) 67 (16.8%) 86 (11.8%)
e5.3) 5.3 (4.8e5.7) 5.5 (5.2e5.8)
) 13 (3.3%) e
.8%) 29 (7.3%) e
.9%) 83 (20.8%) e
.4%) 252 (63.2%) 729 (100.0%)
) 22 (5.5%) e
9e492) 96 (38e151) 290 (120e419)
%) 118 (29.6%) 83 (11.4%)
.4%) 281 (70.4%) 169 (23.2%)
.1%) e 175 (24.0%)
.1%) e 135 (18.5%)
.2%) e 121 (16.6%)
%) e 46 (6.3%)
.6%) 170 (42.6%) 252 (34.6%)
.6%) 118 (29.6%) 250 (34.3%)
.3%) 102 (25.6%) 211 (28.9%)
) 9 (2.3%) 16 (2.2%)
Figure 1 Discontinuation rates per person year of multiple tablet and single tablet regimen third agents (top), and NRTI back-
bone (bottom). EFVZ efavirenz, TDFZ tenofovir, FTCZ emtricitabine, DRV/rZ ritonavir boosted darunavir, ATV/rZ ritonavir
boosted atazanavir, RAL Z raltegravir, 3TC Z lamivudine, ABC Z abacavir, STR Z single tablet regimen, MTR Z multiple tablet
regimen.
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Figure 2 Reasons for discontinuation of multiple tablet regimen third agent and single tablet regimens. MTR Z multiple tablet
regimen, STRZ single tablet regimen, ATPZ co-formulated efavirenz/tenofovir/emtricitabine, EVAZ co-formulated rilpivirine/
tenofovir/emtricitabine, DRV Z darunavir, ATV Z atazanavir, EFV Z efavirenz, RA Z raltegravir.
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We describe the comparative persistence of antiretroviral
therapy by initial regimen in nearly 2000 real-world people
living with HIV in the UK in the UK. Patients enrolled in
clinical studies may not be entirely reflective of the
populations from which they are drawn; the large number
of patients from multiple centres in our analysis provides a
robust view of current day-to-day clinician and patient
choices when initiating and discontinuing antiretroviral
therapy.
It is possible to draw several conclusions from these
data. Firstly, for patients in the UK, discontinuation of
initial treatment is not an uncommon event. The discon-
tinuation rate of third agent and NRTI backbone of 28 (95%
CI 26e31) and 15 (95% CI 14e17) per hundred person-years
respectively are comparable to those seen in other high-
income settings: in an Italian cohort of 4052 patients
starting ART between 2008 and 2014, discontinuation rates
at 1,2 and 3 years were 26%,40% and 49%, respectively.8
These are similar to data from British Columbia, Canada,
where the ART discontinuation rates of 2107 patients who
initiated therapy between 2006 and 2010 were 36%, 47%
and 53% at 1, 2 and 3 years,9 and Switzerland, where the
rate of discontinuation of initial treatment in 1318 treat-
ment-na€ıve patients was 42 per 100 person-years (95% CI
38e46).10 Older data from the UK are available from the
UK CHIC cohort11; of 4583 patients initiating ART between
2000 and 2010, 15e19% discontinued therapy after one
year (with exact proportion dependent on CD4 count); how-
ever, when patients who were also enrolled in the SPARTAC
study of ART at seroconversion were excluded, the remain-
ing 1746 patients had one-year discontinuation rates of
28e31%, highlighting the difference between clinical trial
and real-world populations.
Secondly, in common with other studies, we found
that where the reasons for discontinuation of therapy
were recorded, they were overwhelmingly due to
toxicity or simplification rather than virologic failure.However, the large proportion of records with missing
data warrant caution in drawing any firm conclusions in
this regard.
Thirdly, we observed significant differences in persis-
tence with therapy across ART components. The rates of
discontinuation of RPV as co-formulated RPV/TDF/FTC
were considerably lower than all other considered regi-
mens. Though the missing data on reasons for discontinu-
ations make it difficult to draw firm conclusions, the fact
that overall discontinuations in our cohort are driven by
toxicity and simplification makes it likely that the very low
rates seen in patients taking co-formulated RPV/TDF/FTC
are driven by the favourable side effect profile and possibly
the convenience of a STR. When examining MTR NRTI
backbone we found a less striking, though still statistically
significant, difference in rates of discontinuation of TDF/
FTC and ABC/3TC, with lower rates of discontinuation of
TDF/FTC. Rates of discontinuation of EFV/TDF/FTC were
similar to MTR EFV.
Our study has a number of limitations. Most impor-
tantly, the data are retrospective and observational;
decisions on choice of initial regimen and whether to
discontinue are complex and result from a combination of
clinician, patient, virus and drug characteristics. The
persistence of co-formulated RPV/TDF/FTC may be due
to the characteristics of the patients that clinicians in the
UK are choosing to start on this regimen as well as the
qualities of the regimen itself. In addition, decisions to
switch therapy are based both upon the tolerability of the
regimen and the availability of alternatives; the availabil-
ity of newer STR containing elvitegravir or dolutegravir
(which were infrequent in the local treatment databases
and hence excluded from the analysis) could reduce the
persistence of the regimens we have examined in the
future. In addition, our data are aggregated; without
individual-level data we are unable to perform a survival
analysis to characterise the timing of treatment discon-
tinuation, or to identify factors predictive of treatment
discontinuation. This raises the possibility of selection bias
Figure 3 Reasons for discontinuation of NRTI backbone. STR Z single tablet regimen, TDF Z tenofovir, FTC Z emtricitabine,
ABC Z abacavir, 3TC Z lamivudine.
406 J.M. Lewis et al.of patients with more characteristics predictive of remain-
ing on therapy towards RPV/TDF/FTC. We did not collect
data on resistance patterns or HLA-B*5701 status, factors
which will heavily influence initial ART regimen and the
choice to discontinue.
In addition, mean follow up times were short, at
around a year. The aggregate nature of the data means
that the length of follow up of individual patients is not
available, and so it is not possible to say how many
patients were followed up for less than a year; however
the fact that around a third of patients were recruited in
the year prior to administrative censoring means that a
significant minority of patients had follow up times of less
than a year. This raises the possibility that, for some ART
regimens, the discontinuation rate may be higher in the
first year of therapy but a lower rate (for those remaining
on therapy) for subsequent years on treatment; the lack
of longer term follow up in these data do not allow this
question to be addressed but caution should be exercised
in extrapolating our results to long-term durability of
treatment.
Despite these limitations, this study provides an insight
into real life decisions with regard to initiation and
discontinuation of ART in the UK, and the differential
persistence of ART regimens in current use. These data
may prove useful in guiding initial ART choice. Ultimately, a
robust understanding of persistence and the determinants
of persistence across available ART regimens will provide
clinicians and patients with the tools needed to guide
individualised ART, and maximise the chances of good
outcomes for people living with HIV.
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